Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical …

…, MS Ahluwalia, K Fink, F Di Meco, F Lieberman… - Jama, 2017 - jamanetwork.com
Importance Tumor-treating fields (TTFields) is an antimitotic treatment modality that
interferes with glioblastoma cell division and organelle assembly by delivering low-intensity …

Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial

…, DM Steinberg, SA Toms, LP Taylor, F Lieberman… - Jama, 2015 - jamanetwork.com
Importance Glioblastoma is the most devastating primary malignancy of the central nervous
system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (…

[HTML][HTML] Induction of CD8+ T-cell responses against novel glioma–associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic …

…, IF Pollack, AM Salazar, FS Lieberman - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
Purpose A phase I/II trial was performed to evaluate the safety and immunogenicity of a novel
vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic peptides …

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

…, LM DeAngelis, HI Robins, FS Lieberman… - Neuro …, 2008 - academic.oup.com
The North American Brain Tumor Consortium (NABTC) uses 6-month progression-free survival
(6moPFS) as the efficacy end point of therapy trials for adult patients with recurrent high-…

Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy

…, RL Schilsky, S Bain, EJ Berghorn, F Lieberman - Seminars in …, 2006 - Elsevier
Peripheral neuropathy induced by cancer chemotherapy represents a large unmet need for
patients due to the absence of treatment that can prevent or mitigate this common clinical …

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08

…, S Chang, L Junck, D Schiff, F Lieberman… - Clinical Cancer …, 2006 - AACR
Purpose: Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics
of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-…

Differential sensitivity of glioma-versus lung cancer–specific EGFR mutations to EGFR kinase inhibitors

…, CW Brennan, A Heguy, LM Liau, F Lieberman… - Cancer discovery, 2012 - AACR
Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs
through mutations or deletions in the extracellular (EC) domain. Unlike lung cancers with EGFR …

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

…, M Mehta, LM DeAngelis, F Lieberman… - Neuro …, 2010 - academic.oup.com
Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent anaplastic
glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) were …

Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods

…, MJ Oborski, M Hwang, FS Lieberman… - Cancer management …, 2014 - Taylor & Francis
Malignant gliomas consist of glioblastomas, anaplastic astrocytomas, anaplastic
oligodendrogliomas and anaplastic oligoastrocytomas, and some less common tumors such as …

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01 …

…, MR Rossi, JR Razier, LE Abrey, FS Lieberman… - Clinical Cancer …, 2005 - AACR
Purpose: We investigated the molecular effect of the epidermal growth factor receptor (EGFR)
inhibitors erlotinib and gefitinib in vivo on all available tumors from patients treated on …